Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

16 Oct 2018

The investment increases the overall capacity and capabilities of the facility, and its flexibility.

Cambrex is investing approximately $3 million to increase the capacity and efficiency of one of its cGMP manufacturing facilities at its site in Paullo, Milan, Italy. The investment will include the installation of a new 12,000-L reactor, as well as reconfiguration of the layout to allow for the replacement of existing centrifuges with new, more efficient equipment.

Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

The 1,350 m2 (approx. 14,500 sq. ft) facility manufactures intermediates and APIs under GMP conditions, and this investment is part of a campaign by Cambrex of continuous improvement across its global network of manufacturing sites.

“This investment not only increases the overall capacity and capabilities of the facility, but also its flexibility, allowing us to work more efficiently,” commented Aldo Magnini, Managing Director, Cambrex Milan. “The generics portfolio is an important aspect of Cambrex’s business strategy and we have undertaken a number of improvements and expansions at the site to ensure we have the ability to meet the future demands of the industry.”

In June 2018, Cambrex announced an expansion to the R&D laboratories at Paullo, and in 2017 increased the site’s capabilities to handle and manufacture highly potent APIs.

Cambrex currently manufactures over 70 generic APIs which are produced to cGMP standards. The Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant and development and analytical laboratories.

Read More

Related news

Vetter's Skokie facility expansion nears completion

Vetter's Skokie facility expansion nears completion

17 Apr 2019

Expansions will help meet an increase in customer projects; a second extension is in the final planning stage.

Read more 
Catalent to acquire gene therapy leader Paragon Bioservices

Catalent to acquire gene therapy leader Paragon Bioservices

16 Apr 2019

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.

Read more 
Colorcon expands functional film coatings through the CR Alliance with DuPont

Colorcon expands functional film coatings through the CR Alliance with DuPont

15 Apr 2019

The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Exploristics surges ahead with £1m investment

Exploristics surges ahead with £1m investment

15 Apr 2019

The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.

Read more 
Catalent celebrates opening of second Shanghai facility

Catalent celebrates opening of second Shanghai facility

14 Apr 2019

Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.

Read more 
Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

12 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more